Yidu Tech（0EL）株式概要投資持株会社であるYidu Tech Inc.は、中華人民共和国、ブルネイ、シンガポール、および国際的に、ビッグデータと人工知能（AI）技術を基盤としたヘルスケアソリューションを提供している。 詳細0EL ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長4/6過去の実績2/6財務の健全性3/6配当金1/6報酬収益は年間26.53%増加すると予測されています 今年は黒字化を達成 リスク分析財務結果に影響を与える大きな一時的項目 すべてのリスクチェックを見る0EL Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW479,957 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA479,957 investors already sharing narrativesYour Fair Value€Current Price€0.4941.7% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-4b1b2016201920222025202620282031Revenue CN¥1.5bEarnings CN¥128.7mAdvancedSet Fair ValueView all narrativesYidu Tech Inc. 競合他社CompuGroup Medical SE KGaASymbol: HMSE:COPMarket cap: €1.4bDocCheckSymbol: XTRA:AJ91Market cap: €58.9mMeVis Medical SolutionsSymbol: XTRA:M3VMarket cap: €42.6mifa systemsSymbol: HMSE:IS8Market cap: €5.6m価格と性能株価の高値、安値、推移の概要Yidu Tech過去の株価現在の株価HK$0.4952週高値HK$0.7652週安値HK$0.47ベータ1.31ヶ月の変化-2.97%3ヶ月変化-25.19%1年変化-27.41%3年間の変化-20.33%5年間の変化-84.19%IPOからの変化-88.74%最新ニュースReported Earnings • Jul 01Full year 2026 earnings released: EPS: CN¥0.07 (vs CN¥0.11 loss in FY 2025)Full year 2026 results: EPS: CN¥0.07 (up from CN¥0.11 loss in FY 2025). Revenue: CN¥819.3m (up 15% from FY 2025). Net income: CN¥72.7m (up CN¥190.5m from FY 2025). Profit margin: 8.9% (up from net loss in FY 2025). Revenue is forecast to grow 22% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.お知らせ • Jul 01Yidu Tech Inc. announces Annual dividend, payable on September 16, 2026Yidu Tech Inc. announced Annual dividend of HKD 0.0400 per share payable on September 16, 2026, ex-date on September 01, 2026 and record date on September 02, 2026.お知らせ • Jun 30Yidu Tech Inc., Annual General Meeting, Aug 28, 2026Yidu Tech Inc., Annual General Meeting, Aug 28, 2026.お知らせ • Jun 09Yidu Tech Inc. to Report Fiscal Year 2026 Results on Jun 22, 2026Yidu Tech Inc. announced that they will report fiscal year 2026 results on Jun 22, 2026Board Change • May 21Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Linqi Zhang was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Feb 14Yidu Tech Inc. Announces Resignation of Executive Director Dr. Xie Li, Effective February 13, 2026Yidu Tech Inc. announced that Dr. Xie Li has tendered her resignation as an executive Director with effect from February 13, 2026 as she plans to devote more time to her personal matters.最新情報をもっと見るRecent updatesReported Earnings • Jul 01Full year 2026 earnings released: EPS: CN¥0.07 (vs CN¥0.11 loss in FY 2025)Full year 2026 results: EPS: CN¥0.07 (up from CN¥0.11 loss in FY 2025). Revenue: CN¥819.3m (up 15% from FY 2025). Net income: CN¥72.7m (up CN¥190.5m from FY 2025). Profit margin: 8.9% (up from net loss in FY 2025). Revenue is forecast to grow 22% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.お知らせ • Jul 01Yidu Tech Inc. announces Annual dividend, payable on September 16, 2026Yidu Tech Inc. announced Annual dividend of HKD 0.0400 per share payable on September 16, 2026, ex-date on September 01, 2026 and record date on September 02, 2026.お知らせ • Jun 30Yidu Tech Inc., Annual General Meeting, Aug 28, 2026Yidu Tech Inc., Annual General Meeting, Aug 28, 2026.お知らせ • Jun 09Yidu Tech Inc. to Report Fiscal Year 2026 Results on Jun 22, 2026Yidu Tech Inc. announced that they will report fiscal year 2026 results on Jun 22, 2026Board Change • May 21Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Linqi Zhang was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Feb 14Yidu Tech Inc. Announces Resignation of Executive Director Dr. Xie Li, Effective February 13, 2026Yidu Tech Inc. announced that Dr. Xie Li has tendered her resignation as an executive Director with effect from February 13, 2026 as she plans to devote more time to her personal matters.お知らせ • Nov 17Yidu Tech Inc. to Report First Half, 2026 Results on Nov 27, 2025Yidu Tech Inc. announced that they will report first half, 2026 results on Nov 27, 2025お知らせ • Jun 25Yidu Tech Inc., Annual General Meeting, Aug 29, 2025Yidu Tech Inc., Annual General Meeting, Aug 29, 2025.お知らせ • Jun 13Yidu Tech Inc. to Report Fiscal Year 2025 Results on Jun 25, 2025Yidu Tech Inc. announced that they will report fiscal year 2025 results on Jun 25, 2025お知らせ • Jan 27Yidu Tech Inc. Announces Board ChangesYidu Tech Inc. announced that Dr. Xie Li (Dr. Xie) has been appointed as an executive director with effect from 27 January 2025. Dr. Xie Li, MD, PhD, aged 48, has served as the Head of Innovative Medicine and Real-World Evidence Department at Tianjin Happy Life Technology Co. Ltd., since May 2022. Dr. Xie has nearly ten years of experience as a clinical doctor and more than ten years of working experience in the medical affairs, health economics, and outcomes research departments at top ten multinational pharmaceutical companies, and serves as a member of the Professional Committee on Pharmaceutical Policy and Evaluation of the National Association of Health Industry and Enterprise Management and an external expert at the China-Australia Joint Research Center for Infectious Diseases jointly established by Monash University in Australia and Xi'an Jiaotong University Health Science Centre. She has supported the launch of the most successful pharmaceutical products in China and several first-in-class drugs, as well as market access work including medical insurance negotiations, centralized procurement, and commercial insurance. Dr. Xie has extensive industry experience in the medical, pharmaceutical, and health insurance fields. Her major research areas focus on real-world studies and health economics research, collaboration with research institutes and pharmaceutical and medical device companies to promote the application of AI and big data in healthcare and health insurance. Dr. Xie was the awardee of the scientific and technological second prize of Shaanxi Province and the recipient of multiple research grants. She collaborated with research institutions including Shanghai Fudan University, Peking University, Capital Medical University, the Health Development Research Center of the National Health Commission and the Shanghai Health Development Research Center and jointly published the Research Report on the Value Evaluation and Practical Application of High-Value Medical Consumables which is the most complete evaluation system of high-value medical consumables with the most comprehensive value dimension in China, and has published over 20 papers in renowned academic journals and conferences, including the Journal of Hepatology, Hepatology, JAMA Network Open, and ISPOR. Dr. Xie obtained her Doctor of Medicine degree from Xi'an Jiaotong University in December 2019. The board of the company announced that Dr. Yan Jun (Dr. Yan) has tendered his resignation as an executive director the company, with effect from 27 January 2025, to focus on the company's technology research and development work. Dr. Yan has confirmed that he has no disagreement with the Board and there are no other matters relating to his resignation that need to be brought to the attention of the shareholders of the company. Dr. Yan will remain as the Chief Technology Officer of the Company and the Chief AI Scientist of the Group.お知らせ • Nov 11Yidu Tech Inc. to Report First Half, 2025 Results on Nov 21, 2024Yidu Tech Inc. announced that they will report first half, 2025 results on Nov 21, 2024Buy Or Sell Opportunity • Oct 10Now 32% undervaluedOver the last 90 days, the stock has risen 1.5% to €0.40. The fair value is estimated to be €0.58, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last 3 years. Earnings per share has grown by 107%. For the next 3 years, revenue is forecast to grow by 14% per annum. Earnings are also forecast to grow by 63% per annum over the same time period.Reported Earnings • Jul 30Full year 2024 earnings released: CN¥0.18 loss per share (vs CN¥0.63 loss in FY 2023)Full year 2024 results: CN¥0.18 loss per share (improved from CN¥0.63 loss in FY 2023). Revenue: CN¥807.1m (flat on FY 2023). Net loss: CN¥194.9m (loss narrowed 69% from FY 2023). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.Buy Or Sell Opportunity • Jul 02Now 38% undervalued after recent price dropOver the last 90 days, the stock has fallen 5.1% to €0.44. The fair value is estimated to be €0.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last 3 years. Earnings per share has grown by 107%. For the next 3 years, revenue is forecast to grow by 14% per annum. Earnings are also forecast to grow by 58% per annum over the same time period.New Risk • Jul 01New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CN¥195m Forecast net loss in 3 years: CN¥90m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CN¥90m net loss in 3 years). Share price has been volatile over the past 3 months (9.8% average weekly change).Breakeven Date Change • Jul 01No longer forecast to breakevenThe 4 analysts covering Yidu Tech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CN¥42.7m in 2026. New consensus forecast suggests the company will make a loss of CN¥90.0m in 2027.Reported Earnings • Jun 28Full year 2024 earnings released: CN¥0.19 loss per share (vs CN¥0.63 loss in FY 2023)Full year 2024 results: CN¥0.19 loss per share (improved from CN¥0.63 loss in FY 2023). Revenue: CN¥807.1m (flat on FY 2023). Net loss: CN¥194.9m (loss narrowed 69% from FY 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 106% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.お知らせ • Jun 28Yidu Tech Inc., Annual General Meeting, Aug 30, 2024Yidu Tech Inc., Annual General Meeting, Aug 30, 2024.お知らせ • Jun 19Beijing Yier Technology Co., Ltd. Passes Deep Synthetic Service Algorithm Filing of the Cyberspace Administration of ChinaYidu Tech Inc. announced that both the Yidu Happy Health Large Model Algorithm and Yidu Happy Health Large Model Service Algorithm of Beijing Yier Technology Co. Ltd. have recently passed the deep synthesis service algorithm filing of the Cyberspace Administration of China. Leveraging the proprietary intelligent AI medical brain, YiduCore, that accumulated multi-dimensional, quantifiable knowledge graphs over a decade and integrated advanced large model technology, Yidu Tech applies medical intelligence solutions in three major categories of healthcare scenarios, namely research, diagnosis and treatment and public health, to help reduce the cost of healthcare services, enhance the efficiency of the healthcare industry's supply side, and to promote the establishment of an inclusive, precise, and efficient intelligent healthcare system.Buy Or Sell Opportunity • Jun 19Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 14% to €0.43. The fair value is estimated to be €0.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 43% over the last year. Earnings per share has grown by 50%. For the next 3 years, revenue is forecast to grow by 15% per annum. Earnings are also forecast to grow by 65% per annum over the same time period.お知らせ • Jun 15Yidu Tech Inc. to Report Fiscal Year 2024 Results on Jun 27, 2024Yidu Tech Inc. announced that they will report fiscal year 2024 results on Jun 27, 2024Buy Or Sell Opportunity • Jun 11Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 7.9% to €0.44. The fair value is estimated to be €0.56, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 43% over the last year. Earnings per share has grown by 50%. For the next 3 years, revenue is forecast to grow by 15% per annum. Earnings are also forecast to grow by 65% per annum over the same time period.New Risk • Apr 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (CN¥24m net loss in 3 years).Buy Or Sell Opportunity • Apr 11Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 5.0% to €0.46. The fair value is estimated to be €0.58, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 43% over the last year. Earnings per share has grown by 50%. For the next 3 years, revenue is forecast to grow by 15% per annum. Earnings are also forecast to grow by 65% per annum over the same time period.New Risk • Jan 31New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CN¥24m net loss in 3 years). Share price has been volatile over the past 3 months (7.4% average weekly change). Shareholders have been diluted in the past year (4.9% increase in shares outstanding).Recent Insider Transactions • Jan 17Key Executive recently bought €89k worth of stockOn the 11th of January, Xiaoying Feng bought around 182k shares on-market at roughly €0.49 per share. This transaction amounted to 86% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Xiaoying has been a buyer over the last 12 months, purchasing a net total of €171k worth in shares.Reported Earnings • Dec 31First half 2024 earnings released: CN¥0.072 loss per share (vs CN¥0.36 loss in 1H 2023)First half 2024 results: CN¥0.072 loss per share (improved from CN¥0.36 loss in 1H 2023). Revenue: CN¥356.5m (down 25% from 1H 2023). Net loss: CN¥75.8m (loss narrowed 79% from 1H 2023). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Healthcare Services industry in Europe.New Risk • Dec 03New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CN¥350m Forecast net loss in 3 years: CN¥31m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CN¥31m net loss in 3 years). Shareholders have been diluted in the past year (6.0% increase in shares outstanding).お知らせ • Nov 18Yidu Tech Inc. to Report Q2, 2024 Results on Nov 29, 2023Yidu Tech Inc. announced that they will report Q2, 2024 results on Nov 29, 2023New Risk • Aug 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 9.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.5% average weekly change). Minor Risk Shareholders have been diluted in the past year (6.2% increase in shares outstanding).Breakeven Date Change • Jul 06Forecast to breakeven in 2026The 6 analysts covering Yidu Tech expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 50% per year to 2025. The company is expected to make a profit of CN¥53.8m in 2026. Average annual earnings growth of 67% is required to achieve expected profit on schedule.Reported Earnings • Jul 02Full year 2023 earnings released: CN¥0.63 loss per share (vs CN¥0.80 loss in FY 2022)Full year 2023 results: CN¥0.63 loss per share (improved from CN¥0.80 loss in FY 2022). Revenue: CN¥804.7m (down 35% from FY 2022). Net loss: CN¥628.0m (loss narrowed 18% from FY 2022). Revenue is forecast to grow 35% p.a. on average during the next 2 years, compared to a 6.7% growth forecast for the Healthcare Services industry in Europe.お知らせ • Jun 16Yidu Tech Inc. to Report Fiscal Year 2023 Results on Jun 30, 2023Yidu Tech Inc. announced that they will report fiscal year 2023 results on Jun 30, 2023Breakeven Date Change • Feb 03No longer forecast to breakevenThe 4 analysts covering Yidu Tech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CN¥89.3m in 2025. New consensus forecast suggests the company will make a loss of CN¥64.8m in 2025.お知らせ • Feb 02+ 2 more updatesYidu Tech Inc. Announces CEO ChangesYidu Tech Inc. announced that with effect from 1 February 2023, Ms. Gong Yingying has relinquished her role as the Chief Executive Officer in order for the Company to better comply with code provision C.2.1 of the Corporate Governance Code set out in Appendix 14 to the Listing Rules. Following the relinquishment of Ms. Gong as the Chief Executive Officer, Mr. Xu Jiming has been appointed as the Chief Executive Officer in place of Ms. Gong with effect from 1 February 2023. Ms. Gong remains as an executive Director, chairlady of the Board, chairperson of the nomination committee of the Board and a member of the Remuneration Committee. Mr. Xu, aged 39, is a Senior Vice President (Life Sciences Solutions) and Co-founder of the Company and leads and manages the Life Sciences Solutions business of the Company. Mr. Xu has served as the chief technology officer of Yidu Cloud Beijing, a subsidiary of the Company, since October 2015 and the chief executive officer of Tianjin Happy Life, an affiliated company of the Company, since March 2018. Mr. Xu has also served as the deputy director of the Tsinghua University-YiduCloud Intelligent Automated Medical System Joint Research Center since May 2018 and is the co-author of a paper on the application of AI technology in medicine development published in the Nature Medicine journal in January 2019. Mr. Xu is the spouse of Ms. Gong Yingying, an executive Director and the Chairlady of the Board. Mr. Xu has over ten years of experience in the fields of search engine technology, big data and AI. Before joining the Group in October 2015, Mr. Xu worked in the mobile business division of Alibaba where he held the positions of senior architect at UCWeb between June 2015 and October 2015 and general manager of the search product technology center of amap.com between May 2013 and June 2015. Between July 2008 and May 2013, Mr. Xu worked at Baidu Internet Technology Co. Ltd. as a technology manager. Mr. Xu received his master's degree in computer application technology from the Graduate School of the Chinese Academy of Sciences in July 2008 and his bachelor's degree in automation from Tsinghua University in July 2005.Reported Earnings • Dec 30First half 2023 earnings released: CN¥0.36 loss per share (vs CN¥0.47 loss in 1H 2022)First half 2023 results: CN¥0.36 loss per share (improved from CN¥0.47 loss in 1H 2022). Revenue: CN¥474.4m (down 5.5% from 1H 2022). Net loss: CN¥353.5m (loss narrowed 20% from 1H 2022). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Healthcare Services industry in Europe.Reported Earnings • Nov 26First half 2023 earnings released: CN¥0.36 loss per share (vs CN¥0.47 loss in 1H 2022)First half 2023 results: CN¥0.36 loss per share (improved from CN¥0.47 loss in 1H 2022). Revenue: CN¥474.4m (down 5.5% from 1H 2022). Net loss: CN¥353.5m (loss narrowed 20% from 1H 2022). Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Healthcare Services industry in Europe.Board Change • Nov 16Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Linqing Zhang was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Reported Earnings • Jul 30Full year 2022 earnings released: CN¥0.80 loss per share (vs CN¥7.25 loss in FY 2021)Full year 2022 results: CN¥0.80 loss per share (up from CN¥7.25 loss in FY 2021). Revenue: CN¥1.24b (up 43% from FY 2021). Net loss: CN¥762.3m (loss narrowed 79% from FY 2021). Over the next year, revenue is forecast to grow 42%, compared to a 16% growth forecast for the industry in Germany.Breakeven Date Change • Jun 28Forecast to breakeven in 2025The 4 analysts covering Yidu Tech expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 24% per year to 2024. The company is expected to make a profit of CN¥167.4m in 2025. Average annual earnings growth of 57% is required to achieve expected profit on schedule.Reported Earnings • Jun 25Full year 2022 earnings released: CN¥0.80 loss per share (vs CN¥7.25 loss in FY 2021)Full year 2022 results: CN¥0.80 loss per share (up from CN¥7.25 loss in FY 2021). Revenue: CN¥1.24b (up 43% from FY 2021). Net loss: CN¥762.3m (loss narrowed 79% from FY 2021). Over the next year, revenue is forecast to grow 60%, compared to a 22% growth forecast for the industry in Germany.Board Change • Apr 27Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Linqing Zhang was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Recent Insider Transactions • Mar 19Executive Director recently bought €114k worth of stockOn the 16th of March, Shi Zhang bought around 129k shares on-market at roughly €0.88 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €156k more in shares than they have sold in the last 12 months.Reported Earnings • Nov 28First half 2022 earnings: EPS in line with expectations, revenues disappointFirst half 2022 results: CN¥0.47 loss per share. Revenue: CN¥501.9m (flat on 1H 2021). Net loss: CN¥440.8m (flat on 1H 2021). Revenue missed analyst estimates by 38%. Over the next year, revenue is forecast to grow 73%, compared to a 81% growth forecast for the industry in Germany.Executive Departure • Oct 03Non-executive Director Yongmei Gao has left the companyOn the 26th of September, Yongmei Gao's tenure as Non-executive Director ended after 1.1 years in the role. We don't have any record of a personal shareholding under Yongmei's name. Yongmei is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.17 years, which is considered inexperienced in the Simply Wall St Risk Model.Breakeven Date Change • Jul 09Forecast breakeven pushed back to 2024The 4 analysts covering Yidu Tech previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 70% per year to 2023. The company is expected to make a profit of CN¥691.0m in 2024. Average annual earnings growth of 105% is required to achieve expected profit on schedule.株主還元0ELDE Healthcare ServicesDE 市場7D0%-0.2%1.8%1Y-27.4%11.9%4.2%株主還元を見る業界別リターン: 0EL過去 1 年間で11.9 % の収益を上げたGerman Healthcare Services業界を下回りました。リターン対市場: 0ELは、過去 1 年間で4.2 % のリターンを上げたGerman市場を下回りました。価格変動Is 0EL's price volatile compared to industry and market?0EL volatility0EL Average Weekly Movement6.8%Healthcare Services Industry Average Movement4.9%Market Average Movement5.4%10% most volatile stocks in DE Market12.8%10% least volatile stocks in DE Market2.7%安定した株価: 0EL 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 0ELの 週次ボラティリティ ( 7% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2014754Jiming Xuwww.yidutech.com投資持株会社であるイードゥ・テック・インクは、中華人民共和国、ブルネイ、シンガポール、および国際的に、ビッグデータと人工知能（AI）技術を基盤としたヘルスケアソリューションを提供している。同社は、ビッグデータ・プラットフォーム・ソリューション事業、ライフサイエンス・ソリューション事業、健康管理プラットフォーム・ソリューション事業を通じて事業を展開している。ビッグデータプラットフォーム・ソリューション事業では、データインテリジェンスプラットフォームとデータ分析主導型ソリューション、医療、教育、研究、病院管理などのさまざまなシナリオに対応するAIソリューション、全疾患データプラットフォーム、病院や医療機関向けに易優慧和の名称でデータセンターを運営している。ライフサイエンス・ソリューション部門は、アナリティクス主導の臨床開発、実臨床試験とエビデンス、デジタル商品化ソリューションを製薬、バイオテクノロジー、医療機器、その他の企業に提供している。健康管理プラットフォーム・ソリューション事業では、健康管理プラットフォームのアプリケーションおよびソリューションサービス、生の分散した医療データを抽出・構造化・標準化し、深い医療洞察と実用的なソリューションに変換するAI医療頭脳「YiduCore」の運営、保険会社商品の販売、医薬品および関連ハードウェア等の販売、個別化デジタル治療や院外診療サービスの提供を行っている。また、医療機器の販売、保険仲介および技術サービスの提供、医療およびコンピューター技術の研究開発、投資保有活動も行っている。同社は、病院、研究機関、保険会社、医師、患者、規制当局や政策立案者、製薬会社、バイオテクノロジー会社、医療機器会社などのヘルスケア業界関係者にサービスを提供している。2014年に法人化され、中国の北京に本社を置いている。もっと見るYidu Tech Inc. 基礎のまとめYidu Tech の収益と売上を時価総額と比較するとどうか。0EL 基礎統計学時価総額€515.22m収益（TTM）€9.33m売上高(TTM)€105.16m55.2xPER（株価収益率4.9xP/Sレシオ0EL は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計0EL 損益計算書（TTM）収益CN¥819.30m売上原価CN¥520.80m売上総利益CN¥298.50mその他の費用CN¥225.79m収益CN¥72.71m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）0.071グロス・マージン36.43%純利益率8.87%有利子負債／自己資本比率1.8%0EL の長期的なパフォーマンスは？過去の実績と比較を見る配当金0.9%現在の配当利回り51%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/31 15:20終値2026/07/31 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Yidu Tech Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Liping ZhaoChina International Capital Corporation LimitedKai XiaoChina International Capital Corporation LimitedRuili BianCitigroup Inc3 その他のアナリストを表示
Reported Earnings • Jul 01Full year 2026 earnings released: EPS: CN¥0.07 (vs CN¥0.11 loss in FY 2025)Full year 2026 results: EPS: CN¥0.07 (up from CN¥0.11 loss in FY 2025). Revenue: CN¥819.3m (up 15% from FY 2025). Net income: CN¥72.7m (up CN¥190.5m from FY 2025). Profit margin: 8.9% (up from net loss in FY 2025). Revenue is forecast to grow 22% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
お知らせ • Jul 01Yidu Tech Inc. announces Annual dividend, payable on September 16, 2026Yidu Tech Inc. announced Annual dividend of HKD 0.0400 per share payable on September 16, 2026, ex-date on September 01, 2026 and record date on September 02, 2026.
お知らせ • Jun 30Yidu Tech Inc., Annual General Meeting, Aug 28, 2026Yidu Tech Inc., Annual General Meeting, Aug 28, 2026.
お知らせ • Jun 09Yidu Tech Inc. to Report Fiscal Year 2026 Results on Jun 22, 2026Yidu Tech Inc. announced that they will report fiscal year 2026 results on Jun 22, 2026
Board Change • May 21Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Linqi Zhang was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Feb 14Yidu Tech Inc. Announces Resignation of Executive Director Dr. Xie Li, Effective February 13, 2026Yidu Tech Inc. announced that Dr. Xie Li has tendered her resignation as an executive Director with effect from February 13, 2026 as she plans to devote more time to her personal matters.
Reported Earnings • Jul 01Full year 2026 earnings released: EPS: CN¥0.07 (vs CN¥0.11 loss in FY 2025)Full year 2026 results: EPS: CN¥0.07 (up from CN¥0.11 loss in FY 2025). Revenue: CN¥819.3m (up 15% from FY 2025). Net income: CN¥72.7m (up CN¥190.5m from FY 2025). Profit margin: 8.9% (up from net loss in FY 2025). Revenue is forecast to grow 22% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
お知らせ • Jul 01Yidu Tech Inc. announces Annual dividend, payable on September 16, 2026Yidu Tech Inc. announced Annual dividend of HKD 0.0400 per share payable on September 16, 2026, ex-date on September 01, 2026 and record date on September 02, 2026.
お知らせ • Jun 30Yidu Tech Inc., Annual General Meeting, Aug 28, 2026Yidu Tech Inc., Annual General Meeting, Aug 28, 2026.
お知らせ • Jun 09Yidu Tech Inc. to Report Fiscal Year 2026 Results on Jun 22, 2026Yidu Tech Inc. announced that they will report fiscal year 2026 results on Jun 22, 2026
Board Change • May 21Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Linqi Zhang was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Feb 14Yidu Tech Inc. Announces Resignation of Executive Director Dr. Xie Li, Effective February 13, 2026Yidu Tech Inc. announced that Dr. Xie Li has tendered her resignation as an executive Director with effect from February 13, 2026 as she plans to devote more time to her personal matters.
お知らせ • Nov 17Yidu Tech Inc. to Report First Half, 2026 Results on Nov 27, 2025Yidu Tech Inc. announced that they will report first half, 2026 results on Nov 27, 2025
お知らせ • Jun 25Yidu Tech Inc., Annual General Meeting, Aug 29, 2025Yidu Tech Inc., Annual General Meeting, Aug 29, 2025.
お知らせ • Jun 13Yidu Tech Inc. to Report Fiscal Year 2025 Results on Jun 25, 2025Yidu Tech Inc. announced that they will report fiscal year 2025 results on Jun 25, 2025
お知らせ • Jan 27Yidu Tech Inc. Announces Board ChangesYidu Tech Inc. announced that Dr. Xie Li (Dr. Xie) has been appointed as an executive director with effect from 27 January 2025. Dr. Xie Li, MD, PhD, aged 48, has served as the Head of Innovative Medicine and Real-World Evidence Department at Tianjin Happy Life Technology Co. Ltd., since May 2022. Dr. Xie has nearly ten years of experience as a clinical doctor and more than ten years of working experience in the medical affairs, health economics, and outcomes research departments at top ten multinational pharmaceutical companies, and serves as a member of the Professional Committee on Pharmaceutical Policy and Evaluation of the National Association of Health Industry and Enterprise Management and an external expert at the China-Australia Joint Research Center for Infectious Diseases jointly established by Monash University in Australia and Xi'an Jiaotong University Health Science Centre. She has supported the launch of the most successful pharmaceutical products in China and several first-in-class drugs, as well as market access work including medical insurance negotiations, centralized procurement, and commercial insurance. Dr. Xie has extensive industry experience in the medical, pharmaceutical, and health insurance fields. Her major research areas focus on real-world studies and health economics research, collaboration with research institutes and pharmaceutical and medical device companies to promote the application of AI and big data in healthcare and health insurance. Dr. Xie was the awardee of the scientific and technological second prize of Shaanxi Province and the recipient of multiple research grants. She collaborated with research institutions including Shanghai Fudan University, Peking University, Capital Medical University, the Health Development Research Center of the National Health Commission and the Shanghai Health Development Research Center and jointly published the Research Report on the Value Evaluation and Practical Application of High-Value Medical Consumables which is the most complete evaluation system of high-value medical consumables with the most comprehensive value dimension in China, and has published over 20 papers in renowned academic journals and conferences, including the Journal of Hepatology, Hepatology, JAMA Network Open, and ISPOR. Dr. Xie obtained her Doctor of Medicine degree from Xi'an Jiaotong University in December 2019. The board of the company announced that Dr. Yan Jun (Dr. Yan) has tendered his resignation as an executive director the company, with effect from 27 January 2025, to focus on the company's technology research and development work. Dr. Yan has confirmed that he has no disagreement with the Board and there are no other matters relating to his resignation that need to be brought to the attention of the shareholders of the company. Dr. Yan will remain as the Chief Technology Officer of the Company and the Chief AI Scientist of the Group.
お知らせ • Nov 11Yidu Tech Inc. to Report First Half, 2025 Results on Nov 21, 2024Yidu Tech Inc. announced that they will report first half, 2025 results on Nov 21, 2024
Buy Or Sell Opportunity • Oct 10Now 32% undervaluedOver the last 90 days, the stock has risen 1.5% to €0.40. The fair value is estimated to be €0.58, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last 3 years. Earnings per share has grown by 107%. For the next 3 years, revenue is forecast to grow by 14% per annum. Earnings are also forecast to grow by 63% per annum over the same time period.
Reported Earnings • Jul 30Full year 2024 earnings released: CN¥0.18 loss per share (vs CN¥0.63 loss in FY 2023)Full year 2024 results: CN¥0.18 loss per share (improved from CN¥0.63 loss in FY 2023). Revenue: CN¥807.1m (flat on FY 2023). Net loss: CN¥194.9m (loss narrowed 69% from FY 2023). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.
Buy Or Sell Opportunity • Jul 02Now 38% undervalued after recent price dropOver the last 90 days, the stock has fallen 5.1% to €0.44. The fair value is estimated to be €0.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last 3 years. Earnings per share has grown by 107%. For the next 3 years, revenue is forecast to grow by 14% per annum. Earnings are also forecast to grow by 58% per annum over the same time period.
New Risk • Jul 01New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CN¥195m Forecast net loss in 3 years: CN¥90m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CN¥90m net loss in 3 years). Share price has been volatile over the past 3 months (9.8% average weekly change).
Breakeven Date Change • Jul 01No longer forecast to breakevenThe 4 analysts covering Yidu Tech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CN¥42.7m in 2026. New consensus forecast suggests the company will make a loss of CN¥90.0m in 2027.
Reported Earnings • Jun 28Full year 2024 earnings released: CN¥0.19 loss per share (vs CN¥0.63 loss in FY 2023)Full year 2024 results: CN¥0.19 loss per share (improved from CN¥0.63 loss in FY 2023). Revenue: CN¥807.1m (flat on FY 2023). Net loss: CN¥194.9m (loss narrowed 69% from FY 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 106% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.
お知らせ • Jun 28Yidu Tech Inc., Annual General Meeting, Aug 30, 2024Yidu Tech Inc., Annual General Meeting, Aug 30, 2024.
お知らせ • Jun 19Beijing Yier Technology Co., Ltd. Passes Deep Synthetic Service Algorithm Filing of the Cyberspace Administration of ChinaYidu Tech Inc. announced that both the Yidu Happy Health Large Model Algorithm and Yidu Happy Health Large Model Service Algorithm of Beijing Yier Technology Co. Ltd. have recently passed the deep synthesis service algorithm filing of the Cyberspace Administration of China. Leveraging the proprietary intelligent AI medical brain, YiduCore, that accumulated multi-dimensional, quantifiable knowledge graphs over a decade and integrated advanced large model technology, Yidu Tech applies medical intelligence solutions in three major categories of healthcare scenarios, namely research, diagnosis and treatment and public health, to help reduce the cost of healthcare services, enhance the efficiency of the healthcare industry's supply side, and to promote the establishment of an inclusive, precise, and efficient intelligent healthcare system.
Buy Or Sell Opportunity • Jun 19Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 14% to €0.43. The fair value is estimated to be €0.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 43% over the last year. Earnings per share has grown by 50%. For the next 3 years, revenue is forecast to grow by 15% per annum. Earnings are also forecast to grow by 65% per annum over the same time period.
お知らせ • Jun 15Yidu Tech Inc. to Report Fiscal Year 2024 Results on Jun 27, 2024Yidu Tech Inc. announced that they will report fiscal year 2024 results on Jun 27, 2024
Buy Or Sell Opportunity • Jun 11Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 7.9% to €0.44. The fair value is estimated to be €0.56, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 43% over the last year. Earnings per share has grown by 50%. For the next 3 years, revenue is forecast to grow by 15% per annum. Earnings are also forecast to grow by 65% per annum over the same time period.
New Risk • Apr 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (CN¥24m net loss in 3 years).
Buy Or Sell Opportunity • Apr 11Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 5.0% to €0.46. The fair value is estimated to be €0.58, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 43% over the last year. Earnings per share has grown by 50%. For the next 3 years, revenue is forecast to grow by 15% per annum. Earnings are also forecast to grow by 65% per annum over the same time period.
New Risk • Jan 31New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CN¥24m net loss in 3 years). Share price has been volatile over the past 3 months (7.4% average weekly change). Shareholders have been diluted in the past year (4.9% increase in shares outstanding).
Recent Insider Transactions • Jan 17Key Executive recently bought €89k worth of stockOn the 11th of January, Xiaoying Feng bought around 182k shares on-market at roughly €0.49 per share. This transaction amounted to 86% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Xiaoying has been a buyer over the last 12 months, purchasing a net total of €171k worth in shares.
Reported Earnings • Dec 31First half 2024 earnings released: CN¥0.072 loss per share (vs CN¥0.36 loss in 1H 2023)First half 2024 results: CN¥0.072 loss per share (improved from CN¥0.36 loss in 1H 2023). Revenue: CN¥356.5m (down 25% from 1H 2023). Net loss: CN¥75.8m (loss narrowed 79% from 1H 2023). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Healthcare Services industry in Europe.
New Risk • Dec 03New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CN¥350m Forecast net loss in 3 years: CN¥31m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CN¥31m net loss in 3 years). Shareholders have been diluted in the past year (6.0% increase in shares outstanding).
お知らせ • Nov 18Yidu Tech Inc. to Report Q2, 2024 Results on Nov 29, 2023Yidu Tech Inc. announced that they will report Q2, 2024 results on Nov 29, 2023
New Risk • Aug 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 9.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.5% average weekly change). Minor Risk Shareholders have been diluted in the past year (6.2% increase in shares outstanding).
Breakeven Date Change • Jul 06Forecast to breakeven in 2026The 6 analysts covering Yidu Tech expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 50% per year to 2025. The company is expected to make a profit of CN¥53.8m in 2026. Average annual earnings growth of 67% is required to achieve expected profit on schedule.
Reported Earnings • Jul 02Full year 2023 earnings released: CN¥0.63 loss per share (vs CN¥0.80 loss in FY 2022)Full year 2023 results: CN¥0.63 loss per share (improved from CN¥0.80 loss in FY 2022). Revenue: CN¥804.7m (down 35% from FY 2022). Net loss: CN¥628.0m (loss narrowed 18% from FY 2022). Revenue is forecast to grow 35% p.a. on average during the next 2 years, compared to a 6.7% growth forecast for the Healthcare Services industry in Europe.
お知らせ • Jun 16Yidu Tech Inc. to Report Fiscal Year 2023 Results on Jun 30, 2023Yidu Tech Inc. announced that they will report fiscal year 2023 results on Jun 30, 2023
Breakeven Date Change • Feb 03No longer forecast to breakevenThe 4 analysts covering Yidu Tech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CN¥89.3m in 2025. New consensus forecast suggests the company will make a loss of CN¥64.8m in 2025.
お知らせ • Feb 02+ 2 more updatesYidu Tech Inc. Announces CEO ChangesYidu Tech Inc. announced that with effect from 1 February 2023, Ms. Gong Yingying has relinquished her role as the Chief Executive Officer in order for the Company to better comply with code provision C.2.1 of the Corporate Governance Code set out in Appendix 14 to the Listing Rules. Following the relinquishment of Ms. Gong as the Chief Executive Officer, Mr. Xu Jiming has been appointed as the Chief Executive Officer in place of Ms. Gong with effect from 1 February 2023. Ms. Gong remains as an executive Director, chairlady of the Board, chairperson of the nomination committee of the Board and a member of the Remuneration Committee. Mr. Xu, aged 39, is a Senior Vice President (Life Sciences Solutions) and Co-founder of the Company and leads and manages the Life Sciences Solutions business of the Company. Mr. Xu has served as the chief technology officer of Yidu Cloud Beijing, a subsidiary of the Company, since October 2015 and the chief executive officer of Tianjin Happy Life, an affiliated company of the Company, since March 2018. Mr. Xu has also served as the deputy director of the Tsinghua University-YiduCloud Intelligent Automated Medical System Joint Research Center since May 2018 and is the co-author of a paper on the application of AI technology in medicine development published in the Nature Medicine journal in January 2019. Mr. Xu is the spouse of Ms. Gong Yingying, an executive Director and the Chairlady of the Board. Mr. Xu has over ten years of experience in the fields of search engine technology, big data and AI. Before joining the Group in October 2015, Mr. Xu worked in the mobile business division of Alibaba where he held the positions of senior architect at UCWeb between June 2015 and October 2015 and general manager of the search product technology center of amap.com between May 2013 and June 2015. Between July 2008 and May 2013, Mr. Xu worked at Baidu Internet Technology Co. Ltd. as a technology manager. Mr. Xu received his master's degree in computer application technology from the Graduate School of the Chinese Academy of Sciences in July 2008 and his bachelor's degree in automation from Tsinghua University in July 2005.
Reported Earnings • Dec 30First half 2023 earnings released: CN¥0.36 loss per share (vs CN¥0.47 loss in 1H 2022)First half 2023 results: CN¥0.36 loss per share (improved from CN¥0.47 loss in 1H 2022). Revenue: CN¥474.4m (down 5.5% from 1H 2022). Net loss: CN¥353.5m (loss narrowed 20% from 1H 2022). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Healthcare Services industry in Europe.
Reported Earnings • Nov 26First half 2023 earnings released: CN¥0.36 loss per share (vs CN¥0.47 loss in 1H 2022)First half 2023 results: CN¥0.36 loss per share (improved from CN¥0.47 loss in 1H 2022). Revenue: CN¥474.4m (down 5.5% from 1H 2022). Net loss: CN¥353.5m (loss narrowed 20% from 1H 2022). Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Healthcare Services industry in Europe.
Board Change • Nov 16Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Linqing Zhang was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Reported Earnings • Jul 30Full year 2022 earnings released: CN¥0.80 loss per share (vs CN¥7.25 loss in FY 2021)Full year 2022 results: CN¥0.80 loss per share (up from CN¥7.25 loss in FY 2021). Revenue: CN¥1.24b (up 43% from FY 2021). Net loss: CN¥762.3m (loss narrowed 79% from FY 2021). Over the next year, revenue is forecast to grow 42%, compared to a 16% growth forecast for the industry in Germany.
Breakeven Date Change • Jun 28Forecast to breakeven in 2025The 4 analysts covering Yidu Tech expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 24% per year to 2024. The company is expected to make a profit of CN¥167.4m in 2025. Average annual earnings growth of 57% is required to achieve expected profit on schedule.
Reported Earnings • Jun 25Full year 2022 earnings released: CN¥0.80 loss per share (vs CN¥7.25 loss in FY 2021)Full year 2022 results: CN¥0.80 loss per share (up from CN¥7.25 loss in FY 2021). Revenue: CN¥1.24b (up 43% from FY 2021). Net loss: CN¥762.3m (loss narrowed 79% from FY 2021). Over the next year, revenue is forecast to grow 60%, compared to a 22% growth forecast for the industry in Germany.
Board Change • Apr 27Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Linqing Zhang was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Recent Insider Transactions • Mar 19Executive Director recently bought €114k worth of stockOn the 16th of March, Shi Zhang bought around 129k shares on-market at roughly €0.88 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €156k more in shares than they have sold in the last 12 months.
Reported Earnings • Nov 28First half 2022 earnings: EPS in line with expectations, revenues disappointFirst half 2022 results: CN¥0.47 loss per share. Revenue: CN¥501.9m (flat on 1H 2021). Net loss: CN¥440.8m (flat on 1H 2021). Revenue missed analyst estimates by 38%. Over the next year, revenue is forecast to grow 73%, compared to a 81% growth forecast for the industry in Germany.
Executive Departure • Oct 03Non-executive Director Yongmei Gao has left the companyOn the 26th of September, Yongmei Gao's tenure as Non-executive Director ended after 1.1 years in the role. We don't have any record of a personal shareholding under Yongmei's name. Yongmei is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.17 years, which is considered inexperienced in the Simply Wall St Risk Model.
Breakeven Date Change • Jul 09Forecast breakeven pushed back to 2024The 4 analysts covering Yidu Tech previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 70% per year to 2023. The company is expected to make a profit of CN¥691.0m in 2024. Average annual earnings growth of 105% is required to achieve expected profit on schedule.
